Among adults who have both asthma and type 2 diabetes, starting tirzepatide rather than semaglutide made no difference to the chance of an asthma attack over a year. A US multicentre analysis of 16,352 matched patients, published on 7 September 2026, found that 11.0% of the tirzepatide group and 11.1% of the semaglutide group had … Read more
A meta-analysis of 60 studies and more than 1.25 million people, published in Drugs on 12 September 2026, gives the fullest picture yet of what GLP-1 drugs do to muscle, bone and joints. The bone finding is reassuring: no measurable effect on bone mineral density, and none on fractures. The muscle finding is the one … Read more
Eighty per cent of adolescents taking a GLP-1 receptor agonist still had solid food in the stomach when they arrived for a procedure, despite having fasted for a median of 13 hours, well beyond the eight hours standard guidelines ask for. Among healthy adolescents fasting under the same instruction, the figure was 5%. The study, … Read more
Among 216,293 adults with type 2 diabetes, starting an SGLT2 inhibitor was associated with a lower five-year risk of atrial fibrillation than starting a GLP-1 receptor agonist: 4.3% against 4.8%. Starting both classes together came in at 4.2%, statistically indistinguishable from SGLT2 alone. For anyone weighing the two classes with an eye on heart rhythm … Read more
For people with type 2 diabetes who already have nerve damage in their feet, a matched comparison of 39,540 US patients found fewer foot ulcers on GLP-1 receptor agonists than on DPP-4 inhibitors — and nearly twice the rate of Charcot neuroarthropathy, a joint-destroying complication of the foot. Amputation and bone-infection rates were the same … Read more
A meta-analysis of 19 randomised trials behind semaglutide, tirzepatide and liraglutide reports a gap between what those trials recorded and what their own bloodwork showed. Investigators logged malnutrition as an adverse event in 0.12% of participants. Laboratory screening in the same trials found abnormally low lymphocyte counts in 2.90% of people taking active drug, against … Read more
A study published this month in Ophthalmology Retina looked for a link between GLP-1 drugs and non-arteritic anterior ischemic optic neuropathy, a sudden and usually permanent loss of vision in one eye. Across 19,505 adults with type 2 diabetes it found 29 cases in total, and could not rule out either a real effect or … Read more
Metformin and a GLP-1 receptor agonist are one of the most common drug pairings in type 2 diabetes. A case report and literature review published in Kidney360 describes what happens when that combination goes wrong: a 59-year-old woman developed severe metformin-associated lactic acidosis alongside ketoacidosis, while her blood glucose stayed close to normal — the … Read more